Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Maxcyte Q3 2026 Results: Net Loss of $4.76M, Loss Narrows

MaxCyte reported revenue of $10.2 million for the third quarter of 2026, a significant increase from $6.8 million in the prior year period. The company successfully reduced its quarterly net loss to $4.8 million from $12.4 million year-over-year, driven by higher gross profits and a substantial reduction in operating expenses across R&D and sales and marketing.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue10.26.8
Gross profit8.55.2
Profit before tax-4.8-12.4
Net income-4.8-12.4
EPS (diluted, $ a share)$-0.05$-0.12

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+48.7%
Gross margin83.4%
Operating margin-59.5%
Source

10-Q filed with the SEC, NASDAQ: MXCT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Maxcyte, Inc.: key numbers

Share price
$1.18Close, Nov 16
Market cap
$122M
Shares outstanding
103.25MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological ResearchSIC 8731

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Maxcyte, Inc.

All →
8:22 AM ET 8-K
M&A Deal

Maxcyte Signs $125M M&A Deal with Akron BioProducts LLC

MaxCyte has entered into a definitive agreement to acquire Akron BioProducts LLC for $105 million in cash, $20 million in deferred cash payments, and approximately 20.6 million shares of common stock. The acquisition of the GMP-grade reagent supplier is expected to nearly double MaxCyte's revenue and expand its cell therapy manufacturing offerings. The deal is expected to close before the end of 2026, subject to regulatory approvals.

Value
$125M
Counterparty
Akron BioProducts LLC

“Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value.”

Maher Masoud, President and CEO of MaxCyte
8:11 AM ET 8-K
Business Update

Maxcyte Business Update

MaxCyte announced preliminary Q3 2026 core business revenue of approximately $8.1 million, a 26% year-over-year increase. The company also raised its full-year 2026 total revenue guidance to approximately $34 million, up from the previous range of $30 million to $32 million, driven by accelerated instrument purchasing and milestone payments.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.